Farnesoid X Receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through down-regulation of HER2 expression

Tamoxifen (Tam) treatment is a first-line endocrine therapy for estrogen receptor α (ERα) positive breast cancer patients. Unfortunately, resistance frequently occurs and is often related with overexpression of the membrane tyrosine kinase receptor HER2. This is the rationale behind combined treatme...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncogene
Main Authors: Giordano, Cinzia, Catalano, Stefania, Panza, Salvatore, Vizza, Donatella, Barone, Ines, Bonofiglio, Daniela, Gelsomino, Luca, Rizza, Pietro, Fuqua, Suzanne A. W., Andò, Sebastiano
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4482257/
https://ncbi.nlm.nih.gov/pubmed/21499302
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2011.124
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados